U.S. Stock News

IBM (NYSE:IBM) has introduced a sub-1 nanometer "nanostack" chip architecture, described as offering up to 50% more performance or 70% greater energy efficiency compared with current 2 nm chips. The company also launched Anderon, a standalone quantum wafer foundry in the U.S. focused on manufacturing quantum chips at commercial scale. Together, these moves target future AI, data center hardware, and quantum computing demand, and expand IBM's role in semiconductor and quantum...

Comfort Systems USA (FIX) is back in focus after investors digested fresh analyst commentary on its growing project backlog, stronger free cash flow margins, and supportive earnings estimate revisions, alongside recent leadership changes. See our latest analysis for Comfort Systems USA. Despite a sharp 8.1% decline in the 1 day share price return and a softer 7 day share price return, Comfort Systems USA still shows strong momentum, with a 90 day share price return of 45.6% and a very large 5...

UiPath (PATH) is back in focus after mixed Q1 results, where revenue outperformance contrasted with weaker full year billings guidance compared with other automation software stocks, even as new products like Maestro Case gather customer interest. See our latest analysis for UiPath. The share price reaction around UiPath's Q1 release and Maestro Case updates has been choppy. A 6.04% 1 day share price return and 2.53% 7 day share price return sit against a 30 day share price return that is...

Eli Lilly and Company recently received a positive opinion from the European Medicines Agency’s human medicines committee for Jaypirca (pirtobrutinib) to treat adults with chronic lymphocytic leukemia across all lines of therapy, while U.S. Medicare approved a new GLP-1 Bridge program that will give eligible patients access to Zepbound and Foundayo weight-management drugs for a US$50 monthly copay. Together, these developments highlight how Lilly is extending its reach in both oncology and...

Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA approval for Tryngolza (olezarsen) as the first treatment to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia. The company plans a U.S. commercial launch of Tryngolza next month, targeting high risk patients with limited existing options. Ionis also signed a licensing agreement granting Recordati exclusive rights to develop and commercialize zilganersen for Alexander disease outside the U.S.,...

Recently, analyst commentary from Truist pointed to a credible path for Covista’s Chamberlain University to return to mid-to-high single-digit enrollment growth, reinforcing management’s focus on expanding this healthcare education segment. The emphasis on Chamberlain’s potential enrollment recovery highlights how improving student intake at a single, core institution could meaningfully influence Covista’s overall education portfolio and earnings mix. We’ll now examine how this renewed...

Ross Stores (NasdaqGS:ROST) is drawing inflation weary shoppers across income brackets with its value focused, off price model. The company is seeing sustained interest in its brick and mortar stores even as many retailers emphasize digital channels. This contrast highlights Ross Stores' differentiated approach at a time when in person discount shopping continues to appeal to budget conscious consumers. Ross Stores runs an off price retail model built around in store treasure hunt style...

In recent days, analysts raised their consensus revenue forecasts for CRISPR Therapeutics and projected year-over-year EPS growth ahead of the company’s upcoming earnings report. This shift in expectations has drawn attention to how confidence around near-term gene-editing revenue potential may be reshaping perceptions of CRISPR Therapeutics’ business outlook. We’ll now examine how heightened analyst optimism about CRISPR Therapeutics’ near-term revenues could influence the company’s...

With markets watching a softer May jobs report, muted hiring, elevated layoffs, and a Federal Reserve that may be reluctant to shift rates quickly, many investors are taking a fresh look at stocks that could hold up when growth feels less certain. This article focuses on three stocks from a Defensive Sectors screener, all from Utilities, Consumer Staples, and Healthcare, that are directly exposed to the latest labor market news. Each has been selected for financial strength within its sector,...

Recent Share Performance and Business Mix Galaxy Digital (GLXY) has seen mixed share performance recently, with the stock up 3.5% over the past day but down 14.4% over the past week and about 1.1% over the past month. Over the past 3 months, Galaxy Digital is up about 70.6%, with a total return of 46.5% over the past year and a very large gain across the past 3 years. Year to date, the stock is up 18.2%. The company reports annual revenue of US$58,713.02, primarily from its Digital Assets...

Core Natural Resources recently restarted longwall mining at its Leer South mine and secured major contracts across its segments at favorable prices, reinforcing operational momentum despite broader coal industry headwinds. This combination of restored production capacity and contracted volume visibility could meaningfully influence how investors assess the resilience and cash generation profile of the business. We’ll now examine how the Leer South longwall restart and newly secured...

USA Rare Earth (NasdaqGM:USAR) plans to acquire a producing mine in Brazil, with completion targeted for 2026. The company intends to integrate the mine's output into its global value chain to secure non Asian rare earth feedstock. This development is separate from the recent Wheat Ridge facility commissioning and focuses on expanding upstream supply. USA Rare Earth is drawing fresh attention as it moves to add a producing Brazilian mine to its portfolio, reinforcing its role in rare earth...

In June 2026, Campbell’s and Banza launched a new gluten free condensed Chicken Noodle Soup made with chickpea penne pasta, while Campbell’s also announced upcoming retirements and internal promotions in its transformation and communications leadership, and the stock was added to the Russell Small Cap Comp Value Index. This combination of a milestone gluten free product aimed at health-conscious consumers, leadership transitions, and fresh index inclusion highlights how Campbell’s is...

Recent commentary on Laureate Education (LAUR) centers on weak student enrollment growth, flat earnings per share and disappointing free cash flow projections, which raise questions about demand, operational efficiency and the downside risks already reflected in the stock price. See our latest analysis for Laureate Education. At a share price of $37.12, Laureate Education has a 1 month share price return of 16.04% and a 1 year total shareholder return of 60.69%. This puts recent momentum...

Fresh headlines around potential changes to US sanctions on Venezuela have put US oil refiners back in focus, as traders weigh what cheaper heavy crude access could mean for costs, margins, and long term capital plans. This article looks at how that news ties into a curated screener of larger, financially healthier US refining companies, and why the shift in Venezuelan exports away from China toward the US matters for anyone watching energy stocks. Below, you will see 3 stocks from this...

In June 2026, Cleveland Clinic announced a multi-year research collaboration with 10x Genomics to use its Flex Apex, Xenium and future Atera platforms to analyze advanced bladder cancer tumor samples and uncover treatment-response biomarkers for potential diagnostic development. This partnership aims to generate a rich, multimodal dataset that links single-cell and spatial profiles with clinical outcomes, potentially reinforcing 10x Genomics’ role in precision oncology research and future...

Asana (ASAN) is in focus after announcing that its Asana Gov platform has achieved FedRAMP Moderate Authorization. This opens the door to public sector clients that require specific federal security and compliance standards. See our latest analysis for Asana. The FedRAMP news arrives as Asana’s 1 day share price return of 9.08% and 90 day share price return of 12.97% contrast with a sharply weaker year to date share price return of 46.22% and 1 year total shareholder return decline of 47.52%...

In recent months, United Fire Group reported earnings that exceeded expectations and earned a top analyst ranking, highlighting resilient operations and disciplined execution. This combination of positive earnings surprise and attractive value metrics has drawn fresh investor attention to a business already focused on underwriting discipline and expense control. We’ll now examine how this earnings beat and value appeal may influence United Fire Group’s existing investment narrative and...

WD-40 (WDFC) drew fresh attention after Northcoast Research began coverage with a positive rating, coinciding with strong profitability metrics such as a 54.9% gross margin and a 26.1% return on invested capital. See our latest analysis for WD-40. WD-40’s recent momentum has been strong, with a 20.82% 1 month share price return and a 26.21% year to date share price return, while the 3 year total shareholder return sits at 38.26%, indicating that recent optimism is building on a longer record...

Carvana (CVNA) has moved to expand its operations by adding Inspection and Reconditioning Center capabilities to its ADESA Sarasota auction site, creating more reconditioning capacity and a new local inventory pool. See our latest analysis for Carvana. Carvana's expansion in Sarasota comes at a time when the stock has been under pressure in the short term, with the share price down 14.59% over the past 30 days and 22.11% year to date, even as the 3 year total shareholder return exceeds 10x...

Earlier this week, Praxis Precision Medicines announced that the FDA granted Breakthrough Therapy Designation to elsunersen (PRAX-222) for treating seizures in children with SCN2A developmental and epileptic encephalopathy caused by gain-of-function SCN2A variants, based on positive EMBRAVE Part A trial data. The designation, layered on top of multiple US and European rare disease incentives, underscores elsunersen’s potential to address a severe epilepsy with no approved genetically...

Recent Performance Snapshot for ProAssurance Stock ProAssurance (PRA) has drawn investor attention after recent trading, with the stock last closing at $25. Over the past month, the share price return was 4.6%, and about 1.7% over the past 3 months. See our latest analysis for ProAssurance. Looking beyond the past quarter, ProAssurance’s 1-year total shareholder return of 9.5% contrasts with more moderate recent share price gains. This may hint that earlier momentum has cooled and that...

Keysight Technologies (KEYS) is back in focus after its latest quarterly report topped earnings forecasts, with order growth above 30% year on year and management raising revenue expectations for the period. See our latest analysis for Keysight Technologies. Despite the upbeat earnings news, Keysight Technologies’ recent 1-day and 7-day share price returns are both down around 9%, even though the 90-day share price return is up 17.77% and the 1-year total shareholder return is close to 100%...

With long term unemployment rising in the U.S. and more households under pressure, investors are paying closer attention to how reduced spending might feed through to company revenues and profits. Essential consumer goods stocks can sometimes hold up differently when budgets tighten, but the impact is not uniform. This article looks at how this labor market shock connects to larger food, beverage, and personal care companies, and what that might mean for their risk and resilience. Ahead, you...